4年前,ESC与ANA、ACC联合拟制心房颤动(AF)处理指南,如今ESC独立提出AF指南。新指南的要点如下:提出一个AF的计分;病人分类中加“长期持久AF”一项;采用危险谱评估哪些病人接受抗凝剂防止脑卒中受益最多;心率控制方面提出新的指导意见;建议如何采用新抗心律失常药dronedarone(Multaq、Sanofin-Aventis);提出消融治疗的正式指征;提出“上游”治疗防止AF Four years ago, ESC co-authored a guideline for the treatment of atrial fibrillation (AF) with ANA and ACC, and now ESC independently presents the AF guidelines. The main points of the new guideline are as follows: to propose a scoring system for AF; to add “long lasting AF” to patient classification; to use hazard profiles to assess which patients receive anticoagulants to benefit most from stroke; and to provide new guidelines for heart rate control Advice on how to use the new antiarrhythmic drug dronedarone (Multaq, Sanofin-Aventis); put forward the formal indications of ablation therapy; propose “upstream” treatment to prevent AF